Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database

Puntos clave

• Concurrent radiotherapy with tarlatamab yields promising outcomes in extensive-stage small cell lung cancer treatment.
• Overall survival rate improves significantly post-treatment with the combination approach over previous benchmarks.
• Analysis of data from the DLL3 PanTUMOR database explores the effectiveness of new targeted therapies in this cancer type.
• These findings highlight the need for further investigation into combined treatments and their long-term impacts.